KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Asset Writedowns and Impairment (2019 - 2024)

Historic Asset Writedowns and Impairment for Twist Bioscience (TWST) over the last 6 years, with Q3 2024 value amounting to $293000.0.

  • Twist Bioscience's Asset Writedowns and Impairment fell 8088.71% to $293000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $940000.0, marking a year-over-year decrease of 6346.68%. This contributed to the annual value of -$20000.0 for FY2025, which is 10212.77% down from last year.
  • As of Q3 2024, Twist Bioscience's Asset Writedowns and Impairment stood at $293000.0, which was down 8088.71% from $144000.0 recorded in Q2 2024.
  • Twist Bioscience's Asset Writedowns and Impairment's 5-year high stood at $17.5 million during Q3 2022, with a 5-year trough of -$1.0 million in Q2 2020.
  • Its 5-year average for Asset Writedowns and Impairment is $1.3 million, with a median of $293000.0 in 2024.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first surged by 137941.18% in 2022, then tumbled by 9125.65% in 2023.
  • Over the past 5 years, Twist Bioscience's Asset Writedowns and Impairment (Quarter) stood at $248000.0 in 2020, then soared by 373.39% to $1.2 million in 2021, then crashed by 78.36% to $254000.0 in 2022, then decreased by 2.36% to $248000.0 in 2023, then grew by 18.15% to $293000.0 in 2024.
  • Its Asset Writedowns and Impairment was $293000.0 in Q3 2024, compared to $144000.0 in Q2 2024 and $255000.0 in Q1 2024.